Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-745-3 | CAS number: 71-00-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Carcinogenicity
Administrative data
Description of key information
Read-across was done from L-histidine monohydrochloride (HMHC). Based on this result, and on the structural, chemical
and toxicological similarities between L-histidine monohydrochloride (HMHC) and L-histidine, it is concluded that L-histidine is not carcinogenic in F344 rats of either sex.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 453 (Combined Chronic Toxicity / Carcinogenicity Studies)
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- Fischer 344/DuCrj
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories International, Inc.
- Age at study initiation: 5 weeks
- Other: Specific pathogen free
- Housing: polycarbonate cages with wood-chip bedding (5rats/cage)
- Diet : basal diet: CRF-1 ad libitum (Oriental Yeast Inc., Tokyo)
- Water : tap water ad libitum
- Acclimation period: 1 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24+/-1°C
- Humidity (%): 55+/-5%
- Air changes (per hr): air-conditioned room
- Photoperiod (hrs dark / hrs light): 12 hours light/dark cycle - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
HMHC was added to CRF-J powdered basal diet to give final concentrations of 0 (control), 1.25 and 2.5%.
RATIONALE:
These dose levels were selected on the basis of the results of a 13 weeks subchronic toxicity study at doses of 0.31, 0.62. 1.25, 2.5 and 5% in the diet which was performed prior to the present study (Ikezaki et al, 1994). Because the dietary dose level of 5% proved to exert significant toxicity, it was concluded that the maximum tolerable dose is 2.5% in the diet. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The amounts of food consumed were measured in order to calculate the actual intakes of HMHC.
- Duration of treatment / exposure:
- 104 weeks
- Frequency of treatment:
- daily
- Post exposure period:
- 3 weeks
- Remarks:
- Doses / Concentrations:
1.25%
Basis:
nominal in diet - Remarks:
- Doses / Concentrations:
2.5%
Basis:
nominal in diet - No. of animals per sex per dose:
- 50 males and 50 females; 3 groups
- Control animals:
- yes, plain diet
- Details on study design:
- Rats were randomly allocated to three groups (0 (control), 1.25 and 2.5%.), each consisting of 50 males and 50 females.
- Positive control:
- no
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS: Yes, daily
BODY WEIGHT: Yes, once a week for the first 13 wk of the study and then once every 4 wk.
FOOD CONSUMPTION AND COMPOUND INTAKE: Yes, daily
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
HAEMATOLOGY: Yes, blood taken from abdominal aorta - Sacrifice and pathology:
- SACRIFICE
- After treatment, all surviving animals were given basal diet for a further 3 wk and then killed under ether annaesthesia after a 24-hr fast.
GROSS PATHOLOGY: Yes
- After careful gross examination, a complete autopsy was performed.
- Brain, lungs, heart. liver, spleen, adrenal glands. kidneys and testes of each animal were weighed.
- Moribund or dead animals were also autopsied completely to determine the development of tumours.
HISTOPATHOLOGY: Yes
- Tumour masses, as well as all organs and/or tissues were fixed in 10% buffered formalin and paraffin-embedded sections were routinely prepared and stained with haematoxylin and eosin.. - Statistics:
- Differences between mean values were analysed statistically using analysis of variance followed by Dunnett's test or Scheffe's test. The incidences of tumours were compared with the Fisher's exact probability test.
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No statistical significant differences between control and tested animals.
- Mortality:
- no mortality observed
- Description (incidence):
- No statistical significant differences between control and tested animals.
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The total intake of HMHC was clearly dose related. Final survival rate of female rats in the 2.5% group was 74% and slightly lower than those in the two other groups (Table 1).
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Increased parameters in 2.5% HMHC treated male rats. As the haemoglobin molecule contains 8% histidine, these effects might be expected. Indeed, an histidine-rich diet can induce excessive erythropoiesis in rats.
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No toxicological changes were histologically evident in the tested animals.
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Non-neoplastic changes were observed frequently in all groups including the controls, without any significant differences between the groups.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- Lack of any increase in neoplastic lesions
- Details on results:
- GROWTH OF ANIMALS/BODY WEIGHT
The growth curves indicate that in the 2.5% group a significant depression of body weight gain occured for the 76-104-week period in male rats and for week 84-100 in females. Compared to the control group, this corresponds with 4.9% and 6.3% decrease respectively. The mean body weights of both sexes of the 1.25% group were essentially comparable with the controls, although significant differences (P < 0.05) were sporadically noted in male rats at a few time points.
CLINICAL SIGNS AND MORTALITY
Data for final survival rate and mean survival time are summarized in Table 1.
Final survival rate of female rats in the 2.5% group was 74 % and slightly lower than those (88-90%) in the other two groups. Animals in the 2.5% groups of both sexes showed slightly shorter mean survival although these were not statistically significant. The survival rate of female rats after wk 75 in the 2.5% group was slightly lower than those in the other two groups, whereas the survival curves or male rats were similar in both treated and control groups.
FOOD CONSUMPTION AND COMPOUND INTAKE
Data for total intake of the test chemical, estimated from the food consumption data are summarized in Table 1.
HAEMATOLOGY
Statistically significant increases in red blood cell count (P < 0.05), haemoglobin value (P < 0.05), haematocrit (P < 0.01) and platelet count (P < 0.01)
were observed in male rats given 2.5% HMHC, although no significant changes were found in females.
ORGAN WEIGHTS
In females, the relative weights of the brain in the 2.5 % group and of the adrenals in the 1.25 and 2.5% groups were significantly higher (p < 0.05 and 0.01) than the respective control values whereas the absolute weights were comparable in all groups. The absolute lung weights in male rats were significantly lower (P < 0.05) in the 1.25 and 2.5% groups than in the controls.
GROSS PATHOLOGY
The sites, histological types and incidences of tumours in each group of both sexes are summarized in Table 2.
The first autopsy was performed at week 47, when a male rat in the 2.5% group died of a lipoma arising in the submucosa of the rectum. Therefore, all rats surviving beyond the 47-week time point were included in the effective numbers, except for one malein the 1.25% group that died at week 98, for which organs were not available for histopathological examination because of autolysis. The overall incidences of tumours in each group were 100% in males and 52-64% in females. There were no significant differences between the control and treated groups of both sexes in overall tumour incidences. Tumours were found in many organs or tissues in all groups of both sexes, including the control group. In all male groups, tumours of the testes were most frequent, followed by lesions in the adrenals, heamatopoietic organs and pituitary. All testicular tumours were benign interstitial cell tumours, the most frequently encountered spontaneous tumours in F344 rats. In females, tumours of the pituitary, uterus, heamatopoietic organs and mammary glands were common. Tumours were also detected in other organs/tissues of rats of both sexes of all groups, but at low incidences. The incidence of pituitary adenoma in females were relatively high in the treated groups as compared with the control group, but there were no significant differences.
Therefore, the organ distribution and histological types of tumours were essentially the same as those spontaneous tumours described previously in F344 rats.
NON-NEOPLASTIC LESIONS
Non-neoplastic changes were observed frequently in all groups, including control groups, without any significant differences between the groups. Sperm granulomas in the epididymis, which were observed in male rats fed with 5.0% HMHC in the previous subchronic study, were not found in any group in the present study. Indicating that no damage to the tubule epithelium occured with 2.5% HMHC feeding. - Relevance of carcinogenic effects / potential:
- In the present study, although a variety of tumours was noted in all groups, including the control group, the organ distribution and histological types were essentially the same as those of spontaneous tumours described previously in F344 rats.
- Conclusions:
- Therefore it is concluded that HMHC is not carcinogenic in F344 rats of either sex.
- Executive summary:
In this study the long-term toxicity and carcinogenicity effects of histidine were examined in Fischer 344 (FJ44) rats. It is not stated that the study is GLP, however, the methodology is similar to the OECD 453.
Groups of 50 males and 50 females were fed L-histidine monohydrochloridc (HMHC) in their diet at concentrations of 0 [control], 1.25 and 2.5% for 104 weeks. The dose levels were selected based on the results of a previously performed subchronic toxicity study (Ikezaki et al, 1994, Bulletin of the National Institute of Health Sciences 112, 57 -63). In the previous study the body weights were depressed and formation of sperm granulomas in the epididymis was histologically evident in males fed with 5.0% HMHC.
The real HMHC intake was verified and calculated and are indicated in the table below:
Dose (%)
HMHC intake
Daily intake
(mg/kg bw/day)
Total intake
(g/kg bw/104 weeks)
Males
0
0.0
0.0
1.25
472.9
345.2
2.5
955.0
697.2
Females
0
0.0
0.0
1.25
558.4
407.7
2.5
1105.2
806.8
After 104 weeks exposure, the surviving rats were observed for an additional 3 weeks wereafter they were sacrificed.
Only one male rat died during the exposure period. Final survival rate of female rats in the highest dose group was 74 % and thus slightly lower than those (88-90%) in the other two groups. Animals in the 2.5% groups of both sexes showed slightly shorter mean survival although these were not statistically significant. Also, the survival curves or male rats were similar in both treated and control groups.
The growth curves indicated that the 2.5% group had a significant depression of body weight gain (males: 76-104 weeks; females: 84-100 weeks). The mean body weights of both sexes of the 1.25% group were comparable with the controls, although significant differences were sporadically noted at various time points.
In females, the relative weights of the brain and adrenals in the tested groups were significantly higher than the controls, whereas the absolute weights were comparable in all groups. The absolute lung weights in male rats were significantly lower in the tested groups than in the controls.
Statistically significant increases in red blood cell count, haemoglobin value, haematocrit and platelet count were observed in male rats fed with 2.5% HMHC, while no significant changes were found in females.
Non-neoplastic changes were observed frequently in all groups, including control groups, without any significant differences between the groups.
A variety of tumours occured in all groups, including the control group. However, the organ distribution and histological types of tumours were the same as those spontaneously occuring and described previously in F344 rats. No statistically significant increase in the incidence of any tumour was found in the treated groups of either sex.
Therefore, it was concluded that under the present experimental conditions, HMHC is not carcinogenic in F344 rats.
- Endpoint:
- carcinogenicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- Read-across from L-histidine monohydrochloride (HMHC) to L-histidine is considered justified based on strong similarities with regard to chemical structure and metabolic pathways. Orally administered L-histidine will be protonated in the stomach under the influence of the hydrochloric acid present in the gastric juice. Hence, the systemic behaviour of both substances is identical.
- Reason / purpose for cross-reference:
- read-across source
- Conclusions:
- Read-across was done from L-histidine monohydrochloride (HMHC). Based on this result, and on the structural, chemical
and toxicological similarities between L-histidine monohydrochloride (HMHC) and L-histidine, it is concluded that L-histidine is not carcinogenic in F344 rats of either sex. - Executive summary:
Read-across was done from L-histidine monohydrochloride (HMHC).
In this study the long-term toxicity and carcinogenicity effects of histidine were examined in Fischer 344 (FJ44) rats. It is not stated that the study is GLP, however, the methodology is similar to the OECD 453.
Groups of 50 males and 50 females were fed L-histidine monohydrochloride (HMHC) in their diet at concentrations of 0 [control], 1.25 and 2.5% for 104 weeks. The dose levels were selected based on the results of a previously performed subchronic toxicity study (Ikezaki et al, 1994, Bulletin of the National Institute of Health Sciences 112, 57 -63). In the previous study the body weights were depressed and formation of sperm granulomas in the epididymis was histologically evident in males fed with 5.0% HMHC.
The real HMHC intake was verified and calculated and are indicated in the table below:
Dose (%)
HMHC intake
Daily intake
(mg/kg bw/day)
Total intake
(g/kg bw/104 weeks)
Males
0
0.0
0.0
1.25
472.9
345.2
2.5
955.0
697.2
Females
0
0.0
0.0
1.25
558.4
407.7
2.5
1105.2
806.8
After 104 weeks exposure, the surviving rats were observed for an additional 3 weeks wereafter they were sacrificed.
Only one male rat died during the exposure period. Final survival rate of female rats in the highest dose group was 74 % and thus slightly lower than those (88-90%) in the other two groups. Animals in the 2.5% groups of both sexes showed slightly shorter mean survival although these were not statistically significant. Also, the survival curves or male rats were similar in both treated and control groups.
The growth curves indicated that the 2.5% group had a significant depression of body weight gain (males: 76-104 weeks; females: 84-100 weeks). The mean body weights of both sexes of the 1.25% group were comparable with the controls, although significant differences were sporadically noted at various time points.
In females, the relative weights of the brain and adrenals in the tested groups were significantly higher than the controls, whereas the absolute weights were comparable in all groups. The absolute lung weights in male rats were significantly lower in the tested groups than in the controls.
Statistically significant increases in red blood cell count, haemoglobin value, haematocrit and platelet count were observed in male rats fed with 2.5% HMHC, while no significant changes were found in females.
Non-neoplastic changes were observed frequently in all groups, including control groups, without any significant differences between the groups.
A variety of tumours occured in all groups, including the control group. However, the organ distribution and histological types of tumours were the same as those spontaneously occuring and described previously in F344 rats. No statistically significant increase in the incidence of any tumour was found in the treated groups of either sex.
Therefore it is concluded that HMHC is not carcinogenic in F344 rats of either sex.
Based on this result, and on the structural, chemical and toxicological similarities between L-histidine monohydrochloride (HMHC) and L-histidine, L-histidine is under the present experimental conditions considered as to be not carcinogenic in F344 rats of either sex.
Referenceopen allclose all
Table 1: Data food consumption, intake HMHC, final survival rate and mean survival time
Dose (%) |
Food consumption (g/animal/day) |
HMHC intake |
Final survival rate (%) |
Mean survival time (week) (mean±SD) |
||
Daily intake (mg/kg bw/day) |
Total intake (g/kg bw/104 weeks) |
|||||
Males |
0 |
13.4 |
0.0 |
0.0 |
80 |
104.5± 7.8 |
1.25 |
13.3 |
472.9 |
345.2 |
76 |
104.1± 9.3 |
|
2.5 |
13.1 |
955.0 |
697.2 |
76 |
102.4± 12.8 |
|
Females |
0 |
9.3 |
0.0 |
0.0 |
88 |
105.5± 7.2 |
1.25 |
9.2 |
558.4 |
407.7 |
90 |
106.1± 5.4 |
|
2.5 |
8.9 |
1105.2 |
806.8 |
74 |
103.3± 9.8 |
Table 2: Sites and types of tumours in F344 rats given HMHC in the diet for 104 weeks
Sites |
Types of tumours |
Number of rats with tumours |
|||||
Males |
Females |
||||||
0% |
1.25% |
2.5% |
0% |
1.25% |
2.5% |
||
Effective n° of rats |
50 |
49 |
50 |
50 |
50 |
50 |
|
Brain |
Astrocytoma |
0 |
1 |
0 |
1 |
1 |
0 |
Pituitary gland |
Adenoma |
7 |
3 |
8 |
7 |
10 |
12 |
Thyroid gland |
C-cell adenoma |
3 |
1 |
2 |
0 |
1 |
0 |
C-cell carcinoma |
2 |
1 |
1 |
0 |
1 |
1 |
|
Adrenal gland |
Cortical adenoma |
0 |
0 |
1 |
0 |
0 |
0 |
Pheochromocytoma |
9 |
8 |
5 |
1 |
2 |
1 |
|
Malignant Pheochromocytoma |
1 |
1 |
2 |
1 |
0 |
0 |
|
Pancreas |
Islet cell adenoma |
0 |
0 |
2 |
0 |
1 |
1 |
Liver |
Adenoma |
0 |
0 |
1 |
0 |
0 |
0 |
Oral cavity |
Squamous cell carcinoma |
0 |
0 |
1 |
0 |
0 |
0 |
Tongue |
Squamous cell papilloma |
0 |
2 |
0 |
0 |
0 |
0 |
Squamous cell carcinoma |
0 |
0 |
0 |
0 |
1 |
0 |
|
Large intestine |
Lipoma |
0 |
0 |
1 |
0 |
0 |
0 |
Haematopoietic organs |
Mononuclear cell leukemia |
9 |
7 |
4 |
4 |
6 |
6 |
Malignant lymphoma |
0 |
0 |
1 |
1 |
0 |
0 |
|
Spleen |
Fibroma |
1 |
1 |
0 |
0 |
0 |
0 |
Testis |
Interstitial cell tumour |
45 |
49 |
45 |
- |
- |
- |
Mammary gland |
Fibroma |
1 |
0 |
0 |
0 |
1 |
0 |
Fibroadenoma |
2 |
0 |
0 |
3 |
2 |
3 |
|
Adenolipoma |
0 |
0 |
0 |
1 |
0 |
0 |
|
Adenocarcinoma |
0 |
0 |
0 |
0 |
1 |
1 |
|
Ovary |
Scirrhous adenocarcinoma |
- |
- |
- |
1 |
0 |
0 |
Uterus |
Adenoma |
- |
- |
- |
0 |
2 |
2 |
Endometrial stromal polyp |
- |
- |
- |
9 |
6 |
6 |
|
Endometrial stromal sarcoma |
- |
- |
- |
1 |
0 |
1 |
|
Preputial clitoral gland |
Adenoma |
2 |
3 |
1 |
0 |
0 |
1 |
Squamous cell carcinoma |
0 |
0 |
1 |
1 |
1 |
0 |
|
Lung |
Adenoma |
3 |
4 |
1 |
0 |
1 |
0 |
Adenocarcinoma |
0 |
0 |
0 |
1 |
0 |
0 |
|
Kidney |
Lipoma |
1 |
0 |
0 |
0 |
0 |
0 |
Transitional cell papilloma |
0 |
1 |
0 |
0 |
0 |
0 |
|
Skin/subcutis |
Trichoepithelioma |
0 |
0 |
0 |
1 |
0 |
0 |
Keruloacanthoma |
1 |
0 |
0 |
0 |
0 |
0 |
|
Squamous cell papilloma |
1 |
1 |
2 |
0 |
0 |
0 |
|
Fibroma |
1 |
1 |
3 |
0 |
0 |
1 |
|
Lipoma |
0 |
1 |
0 |
1 |
0 |
0 |
|
Malignant schwannoma |
0 |
0 |
1 |
1 |
0 |
0 |
|
Zymbal’s gland |
Squamous cell papilloma |
0 |
2 |
2 |
0 |
1 |
0 |
Squamous cell carcinoma |
0 |
0 |
0 |
0 |
0 |
1 |
|
Harderian gland |
Adenoma |
1 |
0 |
0 |
0 |
0 |
0 |
Abdominal cavity |
Lymphocytic sarcoma |
0 |
0 |
0 |
1 |
0 |
0 |
Mesothelioma |
3 |
3 |
2 |
0 |
0 |
0 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- chronic
- Species:
- rat
Justification for classification or non-classification
The criteria used for the classification of carcinogenicity are depicted in Table 3.6.1 of the CLP regulation No 1272/2008.
As there was no evidence obtained from the carcinogenicity study in rats, HMHC cannot be placed in either category for carcinogens and thus the substance does not require classification acoording to the CLP regulation.
Based on the structural, chemical and toxicological similarities between L-histidine monohydrochloride (HMHC) and L-histidine, the same conclusion in regards to the classification according the CLP regulation applies to L-histidine and L-histidine can therefore not be placed in either category for carcinogens.
Additional information
Read-across was done from L-histidine monohydrochloride (HMHC).
In the study of Ikezaki (1996) rats were dosed with L-histidine monohydrochloridc (HMHC) for 104 weeks, similar to OECD 453. The concentrations were 0 [control], 1.25 and 2.5% in the diet for 104 weeks and correspond to 0, 472.9 and 955 mg/kg bw for male rats and 0, 558.4, 1105.2 mg/kg bw for females.
After 104 weeks exposure, the surviving rats were observed for an additional 3 weeks wereafter they were sacrificed.
Only one male rat died during the exposure period. Final survival rate of female rats in the highest dose group was 74 % and thus slightly lower than those (88-90%) in the other two groups. Animals in the 2.5% groups of both sexes showed slightly shorter mean survival although these were not statistically significant. Also, the survival curves or male rats were similar in both treated and control groups.
In females, the relative weights of the brain and adrenals in the tested groups were significantly higher than the controls, whereas the absolute weights were comparable in all groups. The absolute lung weights in male rats were significantly lower in the tested groups than in the controls.
Non-neoplastic changes were observed frequently in all groups, including control groups, without any significant differences between the groups.
A variety of tumours occured in all groups, including the control group. However, the organ distribution and histological types of tumours were the same as those spontaneously occuring and described previously in F344 rats. No statistically significant increase in the incidence of any tumour was found in the treated groups of either sex.
Therefore, it was concluded that under the present experimental conditions, HMHC is not carcinogenic in F344 rats.
Based on this result, and on the structural, chemical and toxicological similarities between L-histidine monohydrochloride (HMHC) and L-histidine, L-histidine is under the present experimental conditions considered as to be not carcinogenic in F344 rats of either sex.
Justification for selection of carcinogenicity via oral route
endpoint:
The study describes a chronic cancerogenicity test performed on rats
which was carried out according to OECD 453.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)